<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220610055126N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-14</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effect of liquid phase concentrated growth factors with 2% lidocaine in the management of patients with myofascial pain syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the pain control effect of liquid phase concentrated growth factors with Lidocaine 2%, masseter and temporalis muscle trigger points and pain free mouth opening in patients with myofascial pain syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>16</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64074</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment of patients to two groups is done using the random block method and using excel 2021 software, Blinding description: Adjusting the follow-up time of patients so that they do not meet and talk in the waiting room and are not informed about the nature of the injectable substance in the opposite group (single blind).</study_design>
      <phase>3</phase>
      <hc_freetext>patients with myofascial pain syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group of patients, we use LPCGF injection to control the pain of trigger points in one session. First we find the muscle trigger points in the master or temporalis muscle (this step is done by a specialist assistant under the supervision of the tutor in the examination room of the Oral and Maxillofacial Diseases Department). To find the trigger points, touch the muscle with medium to high pressure in all its parts. When a trigger point is found in a muscle that is actually like a relatively hard nodule to the touch, it causes a lot of pain in the patient that was determined to be the right touch; Then we disinfect the patient's skin with medical alcohol. Dot the trigger points with disinfected white cosmetic pencil and then take 10 ml of blood from the patient's vein (this step is done by a specialist assistant under the supervision of a competent nurse in the operating room of the gingival surgery ward). And pass into the white cap plastic tubes (Silfradent S.r.l, Sofia, Italy) without anticoagulants and additives (Figure 1). These tubes are centrifuged immediately using a fixed program device (Medifuge CGF; Silfradent S.r.l, Sofia, Italy) (Figure -2) (this step is performed by a specialist assistant under the supervision of a consultant in the operating room of the gingival surgery department. The exact settings of the centrifuge are as follows: 1. Acceleration for 30 seconds, 2-2700 rpm for 2 minutes, 3-2400 rpm for 4 minutes, 4-2700 rpm for 2 minutes, 5 Reduce the speed for 30 seconds and 6-Stop. At the end of the process, 3 parts of centrifuged blood are obtained: (Figure -3) 1. The upper layer contains platelet-poor plasma (PPP), 2- The middle layer They contain a very large and dense LPCGF, and the lower 3-layer contains red blood cells. As the test tubes do not contain anticoagulants, the injection should be given within 5 minutes. Otherwise, the blood clots and turns into a gel and LPCGF cannot be extracted. Therefore, after centrifugation, the middle layer (LPCGF) is removed within 5 minutes. The patient is then placed in the same examination position for injection. We inject the LPCGF produced by a 2ml syringe with a mesotherapy needle with a 30 gauge (AVA TEB, made in Iran). Hold each point of the trigger muscle on the surface of the skin between the thumb and forefinger or middle finger (whichever is more comfortable) and then insert the needle between the fingers perpendicular to the skin surface. The needle is inserted into the muscle until it enters the exact TrP, which is confirmed by the patient's reaction when reaching the trigger point. After the needle is inserted into each TrP, first aspiration is performed and then the LPCGF is slowly injected at a uniform rate for 60 seconds and then the needle is gently removed. Gum surgery is performed). In all patients, lidocaine 2% by 2ml syringe with needle Gage 30 mesotherapy (AVA TEB, made in Iran) is injected into other masticatory muscles if they are painful, so that in the medial trigeminal muscle, the injection site is near the junction of the muscle with the mandibular body and with external access and in the muscle. The lateral trigeminal is the injection site into the lower head of the muscle in the area of ​​the trigomandibular raphe with intraoral access. All patients in both intervention and control groups are advised to take 500 mg of acetaminophen orally in a maximum of two doses every 8 hours if necessary and 8 hours before the first follow-up session. We also recommend instructions and other forms of treatment strategies, such as a softer diet, changing postural habits, and reducing stress and anxiety in life. Intervention 2: Control group: In this group, similar to the intervention group, we mark the trigger points of the master and temporalis muscles and mark them with a white cosmetic pencil. Then, 1 ml of 2% lidocaine (5 ml vial) with a 2 ml syringe with mesotherapy needle with 30 gauge (AVA TEB, made in Iran), exactly similar to the injection method in the intervention group, after aspiration, 2% lidocaine into Mark the trigger points slowly, inject at a uniform speed for 60 seconds, and then gently remove the needle. Oral and maxillofacial diseases are performed. All injections are performed by a researcher. In both groups, on the day of injection (immediately before injection), VAS (from zero to 10) of each point is evaluated and averaged. Then, one, seven, fourteen and twenty-eight days after the injection (follow-up sessions), the VAS of each point is evaluated again and their mean is recorded. Follow-up time adjustment of patients is done in such a way that they do not meet and talk in the waiting room and are not informed about the nature of the injected substance in the opposite group (single blind). In all patients, lidocaine 2% by 2ml syringe with needle Gage 30 mesotherapy (AVA TEB, made in Iran) is injected into other masticatory muscles if they are painful, so that in the medial trigeminal muscle, the injection site is near the junction of the muscle with the mandibular body and with external access and in the muscle. The lateral trigeminal is the injection site into the lower head of the muscle in the area of ​​the trigomandibular raphe with intraoral access. All patients in both intervention and control groups are advised to take 500 mg of acetaminophen orally in a maximum of two doses every 8 hours if necessary and 8 hours before the first follow-up session. We also recommend instructions and other forms of treatment strategies, such as a softer diet, changing postural habits, and reducing stress and anxiety in life.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as information about the main outcome or the like, can be shared.

When:
Access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
In order to conduct a review or meta-analysis.

Where to obtain:
Email, Fax

How to obtain:
1 month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Marzieh Alimohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Chamran Highway, Evin, Daneshjoo Blvd., School of Dentistry, Shahid Beheshti University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1983969411</zip>
        <telephone>+98 21 2217 5351</telephone>
        <email>m.alimohamadi95@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Marzieh Alimohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Chamran Highway, Evin, Daneshjoo Blvd., School of Dentistry, Shahid Beheshti University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1983969411</zip>
        <telephone>+98 21 2217 5351</telephone>
        <email>m.alimohamadi95@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 15 and 80 years [≥15 and  ≤80]
Presence of at least one trigger point in the masseter or temporalis muscle, previously detected
Patient’s agreement for participation in this study.
Presence of myofascial pain within masseter muscles according to the RDC/TMD (Ia and Ib)</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients being treated or addicted to painkillers and / or drugs that affect muscle function. Such as: muscle relaxants, anti-inflammatory, benzodiazepines
Patients with mental disorders
Patients with neuropathic pain and neurological disorders (trigeminal neuralgia)
Patients with headache
Edentulous patients
Patients after radiotherapy
Pregnancy or lactation
Pain of dental origin
Drug and/or alcohol addiction
Patients with needle phobia
Patients with bleeding disorders
Metabolic (diabetes) and vascular diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group of patients, we use LPCGF injection to control the pain of trigger points in one session. First we find the muscle trigger points in the master or temporalis muscle (this step is done by a specialist assistant under the supervision of the tutor in the examination room of the Oral and Maxillofacial Diseases Department). To find the trigger points, touch the muscle with medium to high pressure in all its parts. When a trigger point is found in a muscle that is actually like a relatively hard nodule to the touch, it causes a lot of pain in the patient that was determined to be the right touch; Then we disinfect the patient's skin with medical alcohol. Dot the trigger points with disinfected white cosmetic pencil and then take 10 ml of blood from the patient's vein (this step is done by a specialist assistant under the supervision of a competent nurse in the operating room of the gingival surgery ward). And pass into the white cap plastic tubes (Silfradent S.r.l, Sofia, Italy) without anticoagulants and additives (Figure 1). These tubes are centrifuged immediately using a fixed program device (Medifuge CGF; Silfradent S.r.l, Sofia, Italy) (Figure -2) (this step is performed by a specialist assistant under the supervision of a consultant in the operating room of the gingival surgery department. The exact settings of the centrifuge are as follows: 1. Acceleration for 30 seconds, 2-2700 rpm for 2 minutes, 3-2400 rpm for 4 minutes, 4-2700 rpm for 2 minutes, 5 Reduce the speed for 30 seconds and 6-Stop. At the end of the process, 3 parts of centrifuged blood are obtained: (Figure -3) 1. The upper layer contains platelet-poor plasma (PPP), 2- The middle layer They contain a very large and dense LPCGF, and the lower 3-layer contains red blood cells. As the test tubes do not contain anticoagulants, the injection should be given within 5 minutes. Otherwise, the blood clots and turns into a gel and LPCGF cannot be extracted. Therefore, after centrifugation, the middle layer (LPCGF) is removed within 5 minutes. The patient is then placed in the same examination position for injection. We inject the LPCGF produced by a 2ml syringe with a mesotherapy needle with a 30 gauge (AVA TEB, made in Iran). Hold each point of the trigger muscle on the surface of the skin between the thumb and forefinger or middle finger (whichever is more comfortable) and then insert the needle between the fingers perpendicular to the skin surface. The needle is inserted into the muscle until it enters the exact TrP, which is confirmed by the patient's reaction when reaching the trigger point. After the needle is inserted into each TrP, first aspiration is performed and then the LPCGF is slowly injected at a uniform rate for 60 seconds and then the needle is gently removed. Gum surgery is performed). In all patients, lidocaine 2% by 2ml syringe with needle Gage 30 mesotherapy (AVA TEB, made in Iran) is injected into other masticatory muscles if they are painful, so that in the medial trigeminal muscle, the injection site is near the junction of the muscle with the mandibular body and with external access and in the muscle. The lateral trigeminal is the injection site into the lower head of the muscle in the area of ​​the trigomandibular raphe with intraoral access. All patients in both intervention and control groups are advised to take 500 mg of acetaminophen orally in a maximum of two doses every 8 hours if necessary and 8 hours before the first follow-up session. We also recommend instructions and other forms of treatment strategies, such as a softer diet, changing postural habits, and reducing stress and anxiety in life.</i_keyword>
      <i_keyword>Control group: In this group, similar to the intervention group, we mark the trigger points of the master and temporalis muscles and mark them with a white cosmetic pencil. Then, 1 ml of 2% lidocaine (5 ml vial) with a 2 ml syringe with mesotherapy needle with 30 gauge (AVA TEB, made in Iran), exactly similar to the injection method in the intervention group, after aspiration, 2% lidocaine into Mark the trigger points slowly, inject at a uniform speed for 60 seconds, and then gently remove the needle. Oral and maxillofacial diseases are performed. All injections are performed by a researcher. In both groups, on the day of injection (immediately before injection), VAS (from zero to 10) of each point is evaluated and averaged. Then, one, seven, fourteen and twenty-eight days after the injection (follow-up sessions), the VAS of each point is evaluated again and their mean is recorded. Follow-up time adjustment of patients is done in such a way that they do not meet and talk in the waiting room and are not informed about the nature of the injected substance in the opposite group (single blind). In all patients, lidocaine 2% by 2ml syringe with needle Gage 30 mesotherapy (AVA TEB, made in Iran) is injected into other masticatory muscles if they are painful, so that in the medial trigeminal muscle, the injection site is near the junction of the muscle with the mandibular body and with external access and in the muscle. The lateral trigeminal is the injection site into the lower head of the muscle in the area of ​​the trigomandibular raphe with intraoral access. All patients in both intervention and control groups are advised to take 500 mg of acetaminophen orally in a maximum of two doses every 8 hours if necessary and 8 hours before the first follow-up session. We also recommend instructions and other forms of treatment strategies, such as a softer diet, changing postural habits, and reducing stress and anxiety in life.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity of masseter muscle trigger points, pain intensity of temporalis muscle trigger points, general pain intensity, painless opening of mouth. Timepoint: At the beginning of the study (before the start of the intervention) and 7, 14 and 28 days. Method of measurement: Visual Analogue Scale for pain intensity and measurement with a graduated millimeter with an accuracy of one millimeter for maximum mouth opening.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>researcher(Marzieh Alimohammadi)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-24</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Faculty of Dentistry, Shahid Beheshti University of Medical Sciences, Shahid Chamran Highway, Evin Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
